undamentalytics Newsletter
Sign in

Fulgent Genetics, Inc. cash flow statement

In fiscal 2025, Fulgent Genetics, Inc.'s operations generated −$102m of cash; it spent $22.6m on capital projects, leaving free cash flow of −$124m. It returned $10.9m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4−141−161415392542721−102−84
Depreciation and amortisation0112223113326252421
Stock-based pay—852238163343444038
Capital spending12432135241922402320
Free cash flow−5−31−2−341055152355−19−124−104
Free cash flow after stock pay—−11−4−4−5197499202−38−64−164−141
Share buybacks——12——00—742501164
Shares issued——37——2924689—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CSTL vs FLGTFLGT vs SDGRFLGT vs MLABFLGT vs TWST

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Fulgent Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fulgent Genetics, Inc.